Inhibition of myostatin signalling or its biological activity has recently emerged as a potential
remedial approach against muscle wasting and degenerative diseases such as muscular …

Genetic deletion of Myostatin, a member of the Transforming Growth Factor-beta family of
signalling molecules, resulted in excessive growth of skeletal muscle. It demonstrated the …

Mutations in myostatin (GDF8) cause marked increases in muscle mass, suggesting that this
transforming growth factor‐β (TGF‐β) superfamily member negatively regulates muscle …

Myostatin is an endogenous, negative regulator of muscle growth determining both muscle
fiber number and size. The myostatin pathway is conserved across diverse species ranging …

Myostatin was identified more than 20 years ago as a negative regulator of muscle mass in
mice and cattle. Since then, a wealth of studies have uncovered the potential involvement of …

In the past 20 years, myostatin, a negative regulator of muscle mass, has attracted attention
as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical …

Background Skeletal muscle growth and maintenance are essential for human health. One
of the muscle regulatory genes, namely myostatin, a member of transforming growth factor-β …

Increasing the size and strength of muscles represents a promising therapeutic strategy for
musculoskeletal disorders, and interest has focused on myostatin, a negative regulator of …

Myostatin is a secreted protein that negatively regulates skeletal muscle mass determining
both muscle fiber number and size. The myostatin pathway is conserved and regulates …

Myostatin, an endogenous negative regulator of skeletal muscle mass, is a therapeutic
target for muscle atrophic disorders. Here, we identified minimum peptides 2 and 7 to …